Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) FCF Margin (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed FCF Margin for 4 consecutive years, with 491.74% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 41360.0% to 491.74% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 960.07% through Dec 2025, up 1915.0% year-over-year, with the annual reading at 960.07% for FY2025, 1915.0% up from the prior year.
  • FCF Margin hit 491.74% in Q4 2025 for Taysha Gene Therapies, up from 1034.19% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 512000.0% in Q1 2022 to a low of 1951.89% in Q2 2024.
  • Historically, FCF Margin has averaged 34049.33% across 4 years, with a median of 584.52% in 2024.
  • Biggest five-year swings in FCF Margin: plummeted -51251179bps in 2023 and later surged 91770bps in 2025.
  • Year by year, FCF Margin stood at 950.42% in 2022, then surged by 54bps to 435.96% in 2023, then tumbled by -108bps to 905.34% in 2024, then surged by 46bps to 491.74% in 2025.
  • Business Quant data shows FCF Margin for TSHA at 491.74% in Q4 2025, 1034.19% in Q2 2025, and 957.56% in Q1 2025.